Belantamab mafodotin clinical trials
11 indexed studies · 4 currently recruiting
- RecruitingPHASE3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
This study compares two treatments for newly diagnosed multiple myeloma in people who can't have a stem cell transplant. It looks at whether one combination of medicines (BRd) works better than another (DRd) to control the cancer and reduce its signs.
For: Multiple Myeloma · Newly Diagnosed Multiple MyelomaUnited States · Argentina · Australia - CompletedPhase I
A platform trial investigating new combinations of therapies in patients with relapsed multiple myeloma
The ProMMise study is testing a new drug called belantamab mafodotin (belamaf) for people with multiple myeloma that has returned after prior treatment. Researchers want to find out how safe and effective it is, both on its own and when combined with standard myeloma medicines.
For: Multiple myelomaUnited Kingdom · England · Wales - Active not recruitingPHASE3
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This study compares a new treatment, Belantamab Mafodotin, with a common combination treatment (Pomalidomide and Dexamethasone) for Multiple Myeloma that has returned or not responded well to past treatments. It aims to see which treatment works better and is safer.
For: Multiple MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
This study is testing a new combination of medicines for multiple myeloma, a type of blood cancer. It aims to find the safest and most effective dose of Belantamab mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone for people whose myeloma has returned or not responded to previous treatments.
For: Multiple MyelomaUnited States · Brazil · Canada - Active not recruitingPHASE1
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
This study looks at a new combination treatment for newly diagnosed multiple myeloma. It combines an existing drug, belantamab mafodotin, with standard treatments (VRd) to see if it's safe and effective, and to find the best dose.
For: Multiple MyelomaUnited States · Australia · Canada - Active not recruitingPHASE1, PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
This study is looking at a new combination of two drugs, Belantamab Mafodotin and Nirogacestat, for people with multiple myeloma that has come back or not responded to previous treatments. The main goal is to find a safe dose and see how well it works.
For: Multiple MyelomaUnited States · Australia · Canada - Active not recruitingPHASE1, PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
This study is looking at a new combination of two drugs, belantamab mafodotin and isatuximab, for people with multiple myeloma that has come back or not responded to previous treatments. It aims to find the safest and most effective dose.
For: Multiple MyelomaUnited States · Australia · Brazil - RecruitingPHASE1, PHASE2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
This study looks at new drug combinations with isatuximab and other treatments for a type of blood cancer called multiple myeloma. It aims to find better ways to treat patients whose cancer has come back or hasn't responded to previous treatments.
For: Plasma Cell Myeloma RefractoryUnited States · Australia · France - RecruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
This study looks at a new way to give belantamab mafodotin, along with other common medicines, for multiple myeloma that has come back or isn't responding well. We want to see if giving it less often can still work well and cause fewer eye side effects.
For: Multiple MyelomaUnited States · France · Germany - RecruitingPHASE1, PHASE2
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
This study looks at a new treatment called belantamab for multiple myeloma, a type of blood cancer. We want to see how safe it is and how well it works, both on its own and when combined with other medicines. It's for people whose myeloma has come back or hasn't responded to previous treatments.
For: Multiple MyelomaUnited States · Argentina · Australia - Active not recruitingPHASE3
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
This study compares two drug combinations for people with multiple myeloma that has come back or not responded well to previous treatments. It aims to see if a new combination with belantamab mafodotin is better or safer than a standard treatment.
For: Multiple MyelomaUnited States · Australia · Brazil